close
randox logo

  • home Home

  • linked_services Solutions keyboard_arrow_down

    • biotech Core Disciplines keyboard_arrow_down

      • View All
      • Quality Control
      • EQA
      • Chemistry
      • Immunoassay
      • Molecular
      • Point of Care
      • Toxicology
      • Food Diagnostics
      • BioSciences
      • BioReagents
      • Veterinary

    • neurology Disease Areas keyboard_arrow_down

      • View All
      • Acute Kidney Injury
      • Alzheimer's Disease
      • Chronic Kidney Disease
      • Chronic Lung Infection
      • Colorectal Cancer
      • Familial Hypercholesterolemia
      • Gastrointestinal
      • Hyperinflammation
      • Immunodeficiency
      • Neurovascular Dysfunction
      • Pancreatic Cancer
      • Urinary Tract Infection
      • Female Bladder Cancer Array
      • Acute Respiratory Distress Syndrome (ARDS)

    • store Online Store

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

    • Our Story
    • Our Vision
    • Partners & Sponsorships
    • Charity Partners
    • Collaborators
    • Careers

  • mail Contact

randox logo
  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu
Randox Health search

Get in touch to discover more

To find out more about the Evidence MultiSTAT or to discuss arranging a demo, enquire now.

Make an Enquiry mail
download Download brochure

humidity_low Sample Type:
Serum

update Time to Result:
Under 40 Minutes

National Institute for Health and Care Excellence (NICE) advises that the best available marker for epithelial ovarian cancer is CA 125 due to the combination of reliability and general availability. Biochip provides the quantitative detection of CA 125 in a serum sample for epithelial ovarian cancer.

Serum CA 125 measurement, an abdominal and pelvic ultrasound, along with the woman’s menopausal status, are used to assess whether a referral for histology or cytology is required. CA 125 levels after chemotherapy is one of the strongest available indicators of disease outcome, and the most important application for monitoring patients with epithelial ovarian cancer.

Applications

  • Primary Care GPs
  • Hospital Labs
  • Gynaecology Departments
  • Oncology Departments
Biomarker
CA 125

Fast Risk Stratification
triages patients into 'low-risk' or 'high-risk' probability.

Biochip Array Technology
provides the quantitative detection of CA 125 in a serum sample for epithelial ovarian cancer

Reduce the Need for Referral
to secondary care for invasive investigative procedures such as histology or cytology

The Evidence MultiSTAT

Evidence MultiSTAT

The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.

Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.

With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.

MultiSTAT Cartridge

The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.

The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.

No other components are required.

Gastro Panel
Prostate Cancer (PCa)
Bladder Cancer (BCa)
Male & Female Hormone